

Asthma Innovation Research

Annual Report

and Financial Statements

for the Year Ended 1 January 2022

Asthma Innovation Research

(Registration number 1168495)

Contents

	<u>Page</u>
Reference and Administrative Details	3
Trustees' Report	4
Statement of Trustees' Responsibilities	7
Statement of Financial Activities	8
Balance Sheet	10
Notes to the Financial Statements	11 to 16

Asthma Innovation Research

(Registration number 1168495)

Reference and Administrative Details

Charity name	The legal name is “Asthma Innovation Research”
Charity Registration Number	1168495 Registered with Charity Commission in England & Wales
Companies House registration	CE007169 Charitable Incorporated Organisation “CIO” Registered with Companies House in England & Wales
Legal structure	Governing document is the Trust Deed establishing the charity. The trustees are all individuals.
Trustees	Dr Jonny Coppel Dr Rahul Chodhari (Chairman) Dr Simon Braithwaite Dr Dominic Fenn Dr Lucy Everson Dr Jessica Kearney
Principal address	Apartment 55 Warwick Building 366 Queenstown Road London SW11 8NJ
Website and Email	www.asthmainnovationresearch.co.uk Jonny.coppel@gmail.com asthmainnovationresearch@gmail.com
Bankers	Metro Bank plc Southampton Row, London
Custodian trustees holding assets	There are no assets held by any custodian trustee or nominee on behalf of the charity

Asthma Innovation Research

(Registration number 1168495)

Trustees' Report

The trustees present the annual report together with the financial statements of the charity for the year ended 1 January 2022.

Objects and activities of the charity

The purposes of the charity are set out in its governing document.

The charity's governing document is a constitution that was drawn up and was approved by the Charity Commission upon registering on 28 July 2016.

The main purpose of Asthma Innovation Research (AIR) as set out by our governing document is to relieve sickness and promote good health by reducing mortality and morbidity due to asthma, in particular in the child population, in particular but not exclusively by:

- (1) training medical students to educate school children, parents and other members of the community about asthma and increase their knowledge of asthma emergency protocols;
- (2) promoting the discussion, the consideration of, and research into matters of asthma;
- (3) publishing results of research and discussion on matters of asthma;
- (4) hosting educational events including, but not limited to, conferences and lectures on topics of importance; and
- (5) providing opportunities to encourage the exchange of ideas.

The main activities undertaken in relation to those purposes during the year.

The main activities undertaken in relation to these purposes are:

- (1) Managing the asthma teaching programmes currently set up in University College London medical school, Cardiff University, Imperial College University and King's College London University. These projects involve training medical students to go into primary and secondary schools and teach school children about asthma to reduce the stigma around the condition and to improve knowledge of the condition and the emergency protocols.
- (2) Attempting to set up the teaching programmes in more medical schools.
- (3) The distribution and advertising of asthma educational booklets that we had previously developed.

Asthma Innovation Research

(Registration number 1168495)

The main activities undertaken during the year to further the charity's purpose for the public benefit.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.

The charity's main objectives and achievements for the year

In this time period we had the following achievements:

- (1) The project continued throughout the COVID 19 pandemic, including as an SSC at UCL and KCL. We now offer both virtual and face to face sessions for the schools and continue to receive excellent feedback from teachers and students.
- (2) We have taught approximately 1,350 school children nationally and at KCL we have collected data to demonstrate the significant impact of the presentation. The project remains in place at 4 universities (UCL, KCL, Imperial and Cardiff) and has been piloted at Cambridge University. The flexibility of virtual teaching has enabled us to reach schools we would not have previously.
- (3) In 2021 we began the joint Camden and Islington launch of Asthmanauts. Using the funding received from these councils, booklets, bookmarks and posters have been professionally printed and have been distributed to Islington and Camden schools and GPs. Distribution to primary schools in Camden and Islington have been via the centralised school nursing teams. We have been given great feedback from these nursing teams. We have delivered to 25 general practices in Islington and 23 in Camden which equates to 75% of the GPs in these boroughs. We have been given excellent feedback from the GPs so far involved, and are reaching out to the final practices yet to return contact. We have been promoting the use of the booklets through social media channels, nursing forums as well as tracking the number of downloads of the booklets from our website.
- (4) In response to the COVID-19 pandemic, the charity launched a 'Walkie Talkie' project to improve communication in hospitals across the COVID/PPE barriers. After supplying 80 hospitals across the UK with radios spending £8,428, the leftover funds we received from the crowdfunder, were donated, as promised in our campaign, to an NHS charity- the Whittington Health Charity who has purchased an new exhaled nitric oxide analyser which will hopefully make a significant difference in their ability to monitor, investigate and therefore management paediatric asthma.
- (5) Unfortunately our animal mask project in collaboration with Cambridge University has been put on hold due to lack of resources required to drive the project forward.

The contribution of volunteers during the year.

Volunteers, in terms of the Trustees and others have regularly given their time and resources

Asthma Innovation Research

(Registration number 1168495)

during this period with no drain on the charity's funding.

Financial Review

The financial position of the charity at 1 January 2022 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2022	2021
	£	£
Net income/(expenditure)	<u>(312)</u>	<u>1,044</u>
Unrestricted revenue funds for general purposes of the charity	2,620	1,961
Restricted funds	-	971
Total Funds	<u>2,620</u>	<u>2,932</u>

Total income of £4,300 was generated during the financial year 2021/2022, compared to £9,828 raised in the previous 2020/21 year. The 'Walkie Talkie' project in the previous year raised £9,755, before gift aid. In accordance with the fundraising appeal, the remaining funds at the end of this campaign were donated to NHS Charities.

All of the expenditure of £8,784 incurred during the 2020/21 year related to the special project to improve communications in hospitals.

On 1/1/22, AIR had £2,620, which comprises general funds, and there were no restricted funds. There are no concerns about the charity's ability to continue. These unrestricted funds of £2,620 should drive the schools programme forward and will aid the continuing distribution campaign of Princess Asma and Asthmanauts.

Outlook for 2022

The progress in 2022 is likely to be slightly dependent on the restrictions caused by the COVID 19 pandemic. Our main areas of activity are predicted to be:

1. The Schools Education Project. We will continue to offer sessions where possible either face to face or virtually. As always, we will continue to try to spread the project to new medical schools.
2. After a successful Asthmanauts campaign, we will look to distribute in other boroughs of London or other parts of the UK by engaging with local stakeholders.
3. The yoga fundraising series will be recontinued once feasible.

Asthma Innovation Research

(Registration number 1168495)

Statement of Trustees' Responsibilities


The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures
- disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the
- charity will continue in business.
-

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the charity on 6/6/22 and signed on its behalf by:



.....
Dr Jonny Coppel
Trustee



.....
Dr Simon Braithwaite
Trustee

Asthma Innovation Research

(Registration number 1168495)

Statement of Financial Activities (including Income & Expenditure Account) for the Year Ended 1 January 2022

	SORP	Current Year			Prior Year
	Ref	Unrestricted	Restricted	Total	Total
		Funds	Funds	Funds	Funds
		£	£	£	£
Income & Endowments from:					
Donations & Legacies	A1	2,898	1,402	4,300	9,828
Charitable activities	A2	-	-	-	-
Other trading activities	A3	-	-	-	-
Investments	A4	-	-	-	-
Other	A5	-	-	-	-
Total income	A	2,898	1,402	4,300	9,828
Expenditure on:					
Raising funds	B1	-	-	-	-
Charitable activities	B2	2,239	2,373	4,612	8,784
Other	B3	-	-	-	-
Total Expenditure	B	2,239	2,373	4,612	8,784
Net income/(expenditure) for the year	A-B	659	(971)	(312)	1,044
Reconciliation of funds:-	E				
Total funds brought forward		1,961	971	2,932	1,888
Total funds carried forward		2,620	-	2,620	2,932

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

The statement of financial activities includes all gains and losses in the year. All incoming resources and resources expended derive from continuing activities.

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 11 to 16 form an integral part of these accounts.

Asthma Innovation Research

(Registration number 1168495)

Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £	Total Funds 2021 £
Income & Endowments from:				
Donations & legacies	A1	73	9,755	9,828
Expenditure on:				
Raising funds	B1	-	-	-
Charitable activities	B2	-	8,784	8,784
Total expenditure	B	-	8,784	8,784
Net income for the year		73	971	1,044
Net movement in funds		73	971	1,044
Reconciliation of funds:-	E			
Total funds brought forward		1,888	-	1,888
Total funds carried forward		1,961	971	2,932

The statement of financial activities includes all gains and losses in the year. All incoming resources and resources expended derive from continuing activities.

The notes attached on pages 11 to 16 form an integral part of these accounts.

Asthma Innovation Research


(Registration number 1168495)

Balance Sheet as at 1 January 2022

	Note	SORP Ref	2022 £	2021 £
Current assets		B		
Debtors	7	B2	-	-
Cash at bank and in hand		B4	2,620	2,932
Creditors: Amounts falling due within one year	8	C1	-	-
The total net assets of the charity			2,932	2,932
Funds of the charity:				
Unrestricted funds		D3	2,620	1,961
Restricted funds			-	971
Total funds	9		2,620	2,932

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

Approved by the trustees of the charity on 6/6/22 and signed on its behalf by:



.....
Dr Jonny Coppel
Trustee



.....
Dr Simon Braithwaite
Trustee

The notes attached on pages 11 to 16 form an integral part of these accounts.

Asthma Innovation Research

(Registration number 1168495)

Notes forming part of the Financial Statements for the year ended 1 January 2022

1 Accounting policies

The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and in the preceding year.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

Basis of preparation

Asthma Innovation Research meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable, and the amount can be reliably measured.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a

Asthma Innovation Research

(Registration number 1168495)

basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Grant provisions

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees' meetings and reimbursed expenses.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Research and development

Research and development expenditure is written off as incurred.

Trade debtors

are amounts due from customers for merchandise sold or services performed in the ordinary course of business are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of is established when there is objective evidence that they will not be able to collect all amounts due according to the original terms of the receivables.

Asthma Innovation Research

(Registration number 1168495)

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees' discretion in furtherance of the objectives of the charity. Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Asthma Innovation Research

(Registration number 1168495)

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled, or expires.

Fair value measurement

The best evidence of fair value is a quoted price for an identical asset in an active market. When quoted prices are unavailable, the price of a recent transaction for an identical asset provides evidence of fair value as long as there has not been a significant change in economic circumstances or a significant lapse of time since the transaction took place. If the market is not active and recent transactions of an identical asset on their own are not a good estimate of fair value, the fair value is estimated by using a valuation technique.

2 Income from donations and legacies

	Unrestricted	Restricted	Total 2022	Total 2021
	£	£	£	£
Donations and legacies:				
Donations from individuals	48	1,402	1,450	9,828
Other donations	2,850	-	2,850	-
Regular giving and capital donations	-	-	-	-
	2,898	1,402	4,300	9,828

3 Expenditure on raising funds

There were no costs incurred in generating the donations and voluntary income.

4 Expenditure on charitable activities

	Unrestricted	Restricted	Total 2022	Total 2021
	£	£	£	£
Governance costs	-	-	-	-
Costs of charitable activities	2,239	2,373	4,612	8,784
	2,239	2,373	4,612	8,784

Asthma Innovation Research

(Registration number 1168495)

The costs of charitable activities related to printing materials and other resources acquired during 2021/22, together with the distribution of all of the remaining restricted funds to Whittington Health Charity. In the prior year 2020/21, it related to the provision of walkie-talkie radios to 80 hospitals.

5 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

6 Taxation

The charity is a registered charity and is therefore exempt from taxation.

7 Debtors

No debtors were outstanding at the end of the financial year.

8 Creditors: amounts falling due within one year

No creditors were outstanding at the end of the financial year.

9 Funds

	Balance at 2 January 2021	Incoming resources	Resources expended	Balance at 1 January 2022
Unrestricted funds				
General	1,961	2,898	2,239	2,620
<hr/>				
	Balance at 2 January 2021	Incoming resources	Resources expended	Balance at 1 January 2022
Restricted funds				
General	971	1,402	2,373	-

Asthma Innovation Research

(Registration number 1168495)

10 Analysis of net assets between funds

	General Funds	Designated Funds	Restricted Funds	Total Funds
Current assets	2,620	-	-	2,620
Net assets at 1 January 2022	<u>2,620</u>	<u>-</u>	<u>-</u>	<u>2,620</u>

11 Analysis of net funds

	At 2 January 2021 £	Cash flow £	At 1 January 2022 £
Cash at bank and in hand	2,932	(312)	2,620
Net funds	<u>2,932</u>	<u>(312)</u>	<u>2,620</u>